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Opinion statement
Palliative care integrated into standard medical oncologic care will transform the way we
approach and practice oncologic care. Integration of appropriate components of palliative
care into oncologic treatment using a pathway-based approach will be described in this
review. Care pathways build on disease status (early, locally advanced, advanced) as well
as patient and family needs. This allows for an individualized approach to care and is the
best means for proactive screening, assessment, and intervention, to ensure that all
palliative care needs are met throughout the continuum of care. Components of palliative
care that will be discussed include assessment of physical symptoms, psychosocial dis-
tress, and spiritual distress. Specific components of these should be integrated based on
disease trajectory, as well as clinical assessment. Palliative care should also include family
and caregiver education, training, and support, from diagnosis through survivorship and
end of life. Effective integration of palliative care interventions have the potential to
impact quality of life and longevity for patients, as well as improve caregiver outcomes.
Introduction
Lung cancer is a devastating disease and is the leading
cause of cancer-related mortality in the USA [1]. The last
few decades has shown an accelerated rise in technolo-
gies and therapies in non-small-cell lung cancer
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(NSCLC) treatment. Current oncology care focuses on
treatment choices that include radiation therapy, inter-
ventional procedures including surgery, and systemic
therapy [2]. Despite these advances, patients with
NSCLC face many challenges that are not addressed by
our current model of care. NSCLC patients experience
high symptom burden, rapidly declining functional sta-
tus, social decline, psychological symptoms including
emotional and spiritual angst, and often confront a poor
prognosis.
Palliative care focuses on relief of symptoms across
the physical and psychosocial domains and promotes
shared decision-making. Palliative care services should
also include relief and support for family members and
caregivers. Although traditionally implemented late in a
patients’ disease course, palliative care is gaining mo-
mentum and has the potential not only to affect a
patients’ quality of life but also to significantly alter
disease trajectory, and may even prolong survival [3,
4••, 5]. Services must be rendered to patients across
the spectrum of disease and fine-tuned according to a
patient’s individual needs. Importantly, as the world
moves toward delivering more fiscally responsible, high
value care, the integration of palliative care into onco-
logic care has the potential for improving quality of care
as well [6–9].
The purpose of this review is to take a comprehensive
look at the relevant published studies since 2000 to
highlight some of the main advances and potential im-
pact of palliative care integration into the treatment of
non-small-cell lung cancer (NSCLC). This data will be
used to provide recommendations on palliative care
interventions to be included as part of care pathways
for patients with NSCLC.
Palliative therapies
Physical symptoms
Physical symptom burden in NSCLC patients is high and negatively impacts
quality of life [10, 11•, 12]. Pain, dyspnea, cough, anorexia/cachexia, and
fatigue are the five most common and distressing symptoms [13]. Patients with
early-stage lung cancer may experience minimal symptoms; however, as the
disease becomes more advanced, symptoms are more prevalent. An integrated
palliative approach to care would include validated instruments to measure
symptom severity routinely. Subsequent referral to specialist care when symp-
toms become more severe or complex is recommended.
Potential palliative therapeutic approaches to assessing and managing these
common symptoms are outlined below.
Exercise
Fatigue is a common symptom experienced by the NSCLC population that has
an impact on the ability to exercise and maintain functional status. Individuals
with NSCLC engaged in less physical activity to similar aged healthy individ-
uals. They also had higher levels of depression, spent less time outdoors, and
had lower motivation to engage in exercise [14]. Patients who have undergone
lung resection therapy show deterioration in walking distance [15]. Patients
with inoperable lung cancer undergoing chemotherapy tend to be more debil-
itated [16].
Based off growing data, promotion of physical activity is justified, feasible,
and well tolerated during and after cancer therapy. Interventions, both pre- and
post-operatively, have shown positive benefits including in cancer-related fa-
tigue severity, emotional well-being, functional status, and overall quality of
life. Patients who were referred earlier in the course of their treatments were
more likely to adhere to and tolerate physical activity [17•, 18, 19]. In the post-
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surgical setting, several studies have demonstrated the positive effects of exercise
programs on endurance and other quality of life parameters [20–23]. Therefore,
early referral to physical therapy for tailored physical activity recommendations
should be incorporated into NSCLC patient care.
Nutrition
Patients with lung cancer often experience anorexia and cachexia [24–26].
Together, these constitute the cancer anorexia–cachexia syndrome (CACS), a
state of muscle catabolism and weight loss experienced as appetite loss [27].
Weight loss and malnutrition have been associated as independent risk
factors for post-surgical complications such as intensive care support and
post-operative death [28–30]. Data suggests that weight loss during concurrent
chemoradiation therapy for NSCLC starts early and prior to onset of symptoms
[31]. These symptoms may also have a prognostic impact on patients receiving
chemotherapy in advanced disease [32].
Additionally, in advanced disease, the impact of these symptoms can be
profound and can impact ability to deliver appropriate disease-modifying
therapies [33, 34]. It has also been noted that people with advanced cancer
are often found to have fatty acid deficiency [35], which in various studies has
been shown to affect nutritional status, functional status, physical activity, and
quality of life in lung cancer patients during multimodality treatment [36, 37].
Research suggests that interventions such as assessment of nutritional im-
balances and supplementation with appropriate nutrients should be done early
and reevaluated throughout illness trajectory [38, 39]. The use of validated
assessment instruments such as the FAACT scale in patients with CACS should
be utilized to standardize management and follow-up effects of nutritional
interventions [40–42].
Pain management
Approximately 75 % of all cancer patients live with chronic pain. Pain is the
most common symptom for patients with NSCLC, and they experience acute
and chronic pain largely in the chest and lumbar regions [43–45]. Chest pain is
present in an estimated 20 % of patients with lung cancer, and this pain
increases in severity as the disease progresses [46]. Pain is multifactorial, and
thus, often requires a multidisciplinary approach to successful management
[47, 48].
The World Health Organization’s (WHO) Analgesic Ladder for Cancer Pain
Relief is a cornerstone guide for pain management for patients with cancer,
regardless of diagnosis. The ladder describes pain management in a series of
steps as follows: (1) the use of non-steroidal anti-inflammatory drugs
(NSAIDs); (2) weak opioid analgesics; and (3) strong opioid analgesics such
as morphine, oxycodone, or fentanyl [49]. Breakthrough pain, or a temporary
intensification of pain during opioid therapy, may occur and is usually allevi-
ated with immediate release opioids such as fentanyl [47]. Adjuvant analgesics
such as anti-depressants and anti-convulsants can supplement opioid use at any
stage [50].
While opioids are the mainstay of pain management, special consider-
ations must be taken to mitigate side effects. Titration and monitoring is
critical to account for tolerance and metabolic concerns, such as renal
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insufficiency. Additionally, meta-analyses have indicated that opioid use
has resulted in constipation in an average of 41 % of patients. Thus,
laxatives are recommended alongside opioid use to prevent opioid-
induced constipation [51].
More complex cases of refractory pain during the use of analgesics have
shown to benefit from interventional strategies. Radiofrequency ablation is
one way to treat pain due to metastases. In one 2015 study of 12 patients
with rib metastases, pain reported via a visual analogue scale decreased
from 7.9 to 3.4 with no symptomatic complications [52]. For patients
experiencing bone metastases, radiation therapy is indicated. While ques-
tions remain as to the optimal dose and schedule, approximately 40 % of
lung cancer patients receive radiotherapy, and a majority of these are with
palliative intent [53, 54]. Additionally, complementary therapies such as
mind-body modalities, massage, and acupuncture have been accessed by
up to 60 % of cancer patients and have shown a significant benefit [55].
Respiratory support
NSCLC patients often experience a respiratory symptom cluster characterized by
dyspnea and cough, manifesting especially in advanced disease. The prevalence
of dyspnea alone is estimated between 55 and 87 % throughout all stages of
lung cancer [56–59]. Dyspnea correlates with coping capacity, performance
status, and other symptoms such as anxiety, depression, fatigue, and cough
[60]. Further, dyspnea has been shown to account for over 25 % of urgent care
visits in a study of 114 patients with NSCLC, second only to pain [61].
Management of dyspnea relies on the immediate treatment of breathless-
ness with medication and oxygen/air therapy, as well as pulmonary rehabilita-
tion including exercises, breathing retraining, and smoking cessation [58].
Studies have indicated that a combination of pharmaceutical treatment of
underlying causes and longer-term therapies for symptom suppression are the
most effective [62]. These strategies have been shown to reduce breathlessness,
fatigue, and accompanying anxiety while increasing endurance, functional
status, and quality of life [58].
Oxygen therapy is a standard of care for patients requiring respiratory support
[63]. Portable oxygen or high-flow oxygen may be indicated based on a patient’s
oxygen saturation levels. Patients who are not hypoxemic may receive similar
relief of dyspnea using high-flow room air as high-flow oxygen [64].
In patients with refractory dyspnea who no longer experience benefits from
portable or high-flow oxygen, opioids are indicated [65]. A review of the use of
opioids in the management of dyspnea found that oral opioids, specifically
systemic opioids such as once-daily morphine, could increase comfort and
decrease the sensation of breathlessness [66, 67••].
Non-pharmacological therapies that have resulted in symptom management
are largely based in exercises for endurance and breathing efficiency,management
of psychological distress, and lifestyle modifications such as smoking cessation
[67••]. Evidence suggests that exercises such as pursed lip and diaphragmatic
breathing are effective in alleviating dyspnea [67••]. Activities to reduce distress
and improve self-efficacy include breathing exercises, relaxation techniques, and
psychological support provide an additive and lasting therapeutic effect while
promoting self-efficacy in managing dyspnea [67••, 68].
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Psychosocial distress
Palliative care should not only address disease-specific physical complaints and
symptoms but should also include assessment of psychological, social, spiritu-
al, and financial well-being [69, 70]. Psychosocial status appears to mirror
physical decline, particularly surrounding key transition points in a patient’s
disease course; namely, at time of diagnosis, discharge after treatment, as
disease progresses, and at end of life. These may be the time periods to focus
palliative care interventions [71].
For example, it is known that depression and anxiety are common and
persistent symptoms experienced by patients diagnosed with NSCLC ranging
in prevalence between 25 and 50 % and persistent in approximately 50 % of
patients, especially among those with more severe symptoms or functional
limitations [72–74]. There have been several studies linking the presence of
depression as a predictor of worse survival in cancer, including in newly
diagnosed metastatic NSCLC [75–77]. Another study suggests that the presence
of anxiety, depression, and worse psychological quality of life during early stage
of treatment was associatedmore with receipt of chemotherapy at the end of life
[78]. A patients’ specific coping style may be impacted by their mental health
and likely has repercussions on medical decision-making and disease trajectory
[79, 80].
Comprehensive validated assessment instruments to measure psychological
distress such as the distress thermometer should be used. In addition to screen-
ing for depression and anxiety, other areas of concern include family relation-
ships, emotional functioning, lack of information regarding diagnosis/treat-
ment, and practical problems such as financial issues or child care [81]. Referrals
to appropriate specialists, which include social workers, specialized nurses, care
coordinators or casemanagers, financial specialists, mental health professionals
or spiritual counselors should then be made based on initial assessment.
Smoking cessation
Although decreasing, approximately 16.8 % of the adult US population still
smokes cigarettes [82]. Smoking is a known risk factor for NSCLC with current
smoking status conferring a worse overall survival and disease-free survival [83].
Smoking is also a known factor associated with increased risk of developing
mutations such as KRAS and p53 known to be associated with NSCLC [84, 85].
Chronic nicotine exposure impacted response to therapy in EGFR-mutated
NSCLC patents receiving targeted therapy, thus impacting disease trajectory
[86]. An association between smoking and the development of NSCLC-
COPD has been studied [87].
Furthermore, studies have shown that second primary lung cancers were rare
in non-smokers but were associated with increased risk of occurring with
increased tobacco exposure. In contrast, non-smokers, former smokers, and
recent quitters showed a significant better prognosis [88]. Data also exists that
links longer time since cessation of smoking to improve survival outcomes for
NSCLC patients with early disease [89]. Patients who quit smoking after the
diagnosis of NSCLC maintain better performance status [90]. Given such
overwhelming evidence, it is clear that smoking cessation should be prioritized
in the care of all patients, and especially in the NSCLC population.
Smoking cessation is more effective with a combined non-pharmacologic
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and pharmacologic approach. The National Cancer Institute recommends a
five-step behavior change process which includes asking the patient about their
smoking status, assessing their willingness to make a quite attempt, advising
them to stop, assisting them with cessation efforts, and arranging follow-up.
Individual and/or group therapy is often appropriate in addition to nicotine
replacement therapy, which is the mainstay of pharmacologic treatment. Other
medications such as bupropion and varenicline are available, as well as
nortryptiline and clonidine, which are available off label for this purpose.
Routine follow-up is recommended as the more extensive the support, the
higher the likelihood of successful cessation [91–93].
Spiritual health
Palliative care interventions should include content that targets the spiritual
needs of patients, their family members, and caregivers. Spirituality is multidi-
mensional, encompassing constructs such as faith and meaning, which may or
may not be connected to religious affiliations [94]. Religiousness and spiritual-
ity improved depressive symptoms andmay ease end of life distress. Women in
particular may benefit from spiritual support as they reported more intense
problems with emotional functioning and showed benefit from supportive
spiritual care [95, 96]. Attempts should be made for providers to use validated
assessment instruments such as the FICA to quantitatively measure and track
spiritual well-being through treatment course and afterward [97]. Dependent
on results of a needs assessment, engaging spiritual care specialists should be
considered.
Considering the continuum
Early-stage disease pathway and survivorship
Patients with early-stage NSCLC have disease limited either to the lung (0, IA,
IB) or local spread to lymph nodes located on the same side of the chest to
where the cancer started (IIA). When possible, early-stage disease is treated with
surgery to resect the tumor with 5-year survival approximated at approximately
50 % [98].
Given that surgery is the mainstay of therapy for this stage of disease,
perioperative risk stratification and riskmodification are important. Assessment
of physical symptoms, psychosocial distress, spiritual distress, and caregiver
distress should be a common practice for all. However, focus on nutritional
and exercise therapy interventions, along with support for smoking cessation,
are the mainstay of palliative therapy for this stage. Clinicians and patients
should participate in shared decision-makingwith the initiation of advance care
planning efforts.
A survivorship plan should also be developed for patients and families.
Survivors face significant challenges post-treatment. Fatigue and respiratory
symptoms are the most prevalent physical symptoms among NSCLC survivors
and are associated with functional impairment. A comprehensive approach to
treatment of these symptoms also includesmanagement of anxiety, depression,
and pulmonary disorders [99]. Structured exercise programs can improve phys-
ical functioning, mood, respiratory distress, and sleep efficiency [100–102].
Referral to physical activity and pulmonary rehabilitation programs may
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promote higher quality of life outcomes [103].
Other concerns for lung cancer patients post-treatment include psycholog-
ical distress, depression, financial issues, and fear of recurrence of NSCLC or
secondary malignancies [104••]. Psychosocial support, including mental
health support, spiritual support, caregiver support, and financial advice,
should be offered alongside continued medical management of symptom
sequelae.
Locally advanced disease pathway
For patients with locally advanced disease, treatment can be complex and
includes a combination of radiation therapy, systemic therapy, and surgical
interventions, often in sequence or combination [109]. As such, in addition to
the standard clinical assessments and palliative interventions above, there is a
greater need to coordinate a larger multidisciplinary team often involving
medical oncologists, radiation specialists, and surgeons. Discussion of cases in
multidisciplinary teammeeting forums has shown evidence for better treatment
tolerability and outcomes [110]. The evidence from several studies suggest that
earlier integration of specialist palliative care team in this collaborative team
environment is feasible and has a beneficial impact on symptoms and other
quality of life measures [111, 112, 113••].
Advanced disease pathway
The goal of treatment in advanced disease is prolongation of quality of life in
the context of patient goals and values. Family and caregiver distress is often
more acute, and the need for training, education, and support through treat-
ment, end of life, and bereavement is critical. The more common therapeutic
strategies in this setting include radiation for the purposes of palliation of
symptoms and systemic therapy.
Radiation therapy has shown associated improvements in several physical
symptoms including pain, dyspnea, cough, andmoremoderately in fatigue and
appetite loss [114–116]. Overall improvements in physical, cognitive, social,
and emotional functioning were noted, along with beneficial effects on overall
global quality of life [117, 118].
The mainstay of treatment is systemic and includes chemotherapy, immu-
notherapy, and targeted agents, used to improve quality of life. There is a strong
relationship between response to chemotherapy and survival when compared
to best supportive care [119, 120]. Additionally, palliative chemotherapy has
been associated with improvements in several components of symptom relief
and quality of life measures [121–123]. Having said this, continuing chemo-
therapy for advancedNSCLC until very near death is associatedwith a decreased
likelihood of receiving hospice care but not prolonged survival [124]. Beyond
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Adherence to recommendations on surveillance for recurrence and second
primary lung cancers should be followed. The majority of second primary lung
cancers and recurrences were detected by post-therapeutic surveillance comput-
ed tomography (CT) scans. The highest risk of recurrence persisted in the first 2–
4 years following resection with curative intent [105–107]. The American
Association for Thoracic Surgery recommends that long-term lung cancer sur-
vivors have low-dose CT to detect second primary lung cancer until the age of
79 years [108].
three courses of chemotherapy conveys no survival or consistent quality of life
benefits in advanced NSCLC patients [125]. Oncologists should strive to dis-
continue chemotherapy as death approaches and encourage patients to enroll
in hospice for better end of life palliative care.
Considering this evidence, involvement of palliative care specialists is war-
ranted, given the added mental, emotional, psychosocial, and medical com-
plexity of care at this stage of disease. Importantly, involvement of palliative
care specialists is beneficial to find the appropriate timing of transition to
hospice care, which is often accomplished too late in the current model of care.
In this one study, patients with metastatic NSCLC who received early palliative
care measures still received similar number of chemotherapy regimens, but the
timing of final chemotherapy administration and transition to hospice services
were optimized [126].
Special considerations
Lung cancer in geriatric populations
The age at diagnosis for lung cancer ismost often 970 years old, and oncologists
are becoming increasingly aware of this expanding aged cancer population who
face unique physical, psychological, and social challenges when receiving care.
However, it is also becoming acutely apparent that similar to younger patients,
carefully selected elderly patients can benefit from therapy at all stages of
disease, and should not be excluded or under treated on the basis of age alone
[127–131].
There is no significant difference in response or toxicity between younger
and elderly patients receiving palliative radiation therapy [132]. Furthermore,
preliminary studies show that higher doses of radiation are safe, effective, and
may affect survival in aged NSCLC patients [133]. The previous fear that
chemotherapy would be particularly toxic and harmful to elderly patients has
also been quelled [134]. As with any age, consideration of comorbid conditions
and risk factors should be weighed but elderly patients should not be excluded
from this option [135]. Even patients with poor prognostic factors still exhibit
positive response and symptom relief with palliative chemotherapy [136, 137].
Palliative surgical treatments too are being considered more readily in the
elderly given similar benefits and quality of life expectations [138, 139]. As
with other age groups, geriatric populationswant to be involved in the decision-
making process.
Family and caregiver support
Caregivers experience high levels of caregiver burden and reported deterioration
in psychological well-being and overall quality of life [140, 141]. Distress and
anxiety are understudied but accepted as widely prevalent among patients and
their family caregivers. Several common areas of anxiety and distress exist, with
the most prevalent themes emerging as uncertainty, loss or impending loss,
changing roles, conflict outside, finances, physical symptoms, fears of decline
and dying, and life after the patients’ passing [142].
A large area of distress stems from caregiver management of patient symp-
toms. There may be a discrepancy in how lung cancer patients and their
caregivers assess and address both psychological and physical symptom
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occurrence and distress [143, 144]. Patient and caregiver self-efficacy and con-
gruence of self-efficacy for managing pain, symptoms, and function affect
several factors of distress and overall quality of life [145–147].
When given supportive services, both patients and caregivers have
shown improvements in various parameters including pain, depression,
self-efficacy, anxiety, and overall quality of life [148]. Thus, palliative care
interventions aimed at caregiver and patient education, training, and sup-
port should be implemented early and consistently. Supportive efforts
should be continued through treatment into the survivorship phase, and/
or into the bereavement phase.
Advance care planning and transitions in care
Advance care planning (ACP) is a central component of palliative care. It
includes both the medical aspect of care involving discussions with patients
and families regarding goals of care, and the legal aspect of care involving the
completion of either an advance directive form or a POLST. Presently, there are
poor completion rates for ACP [149]. Despite overwhelming evidence that
involvement of palliative services and hospice improve quality of care [150–
152], poor utilization remains [153]. The goal would be to engage specialist
palliative care teams earlier in a patient’s illness trajectory in order tomaximally
utilize resources while prioritizing shared decision-making and patient values.
Limitations
Research using quality of life parameters as outcome measures is becoming
more accepted and widespread. However, most studies evaluating palliative
measures in NSCLC have thus far been small and with mixed results. Research
needs to be reproduced and replicated in order to validate a standardized
approach to comprehensive cancer care for patients with NSCLC that integrates
palliative care as amechanism for ensuring optimal quality of life at any stage of
disease experience (Fig. 1).
Conclusions
Palliative care is a specialized field that aims to provide effective symptom
management and to maximize quality of life for patients and their caregivers
through the entirety of illness trajectory from diagnosis to survivorship and end
of life. Utilizing the care pathways as described in this article allow for person-
alized screening, assessment, and consistent implementation of palliative care
interventions for patients and their families.
Initial treatment plan for all patients, regardless of stage, should encompass
early assessment of clinical domains including physical symptoms, psychoso-
cial distress, spiritual distress, and caregiver distress. Subsequent implementa-
tion of interventions and specialist referrals should be made based off needs of
patients and caregivers.
In early-stage disease, the focus is primarily on surgical risk assessment and
modification with particular attention paid to nutritional interventions and
implementation of exercise training programs. It is essential that in post-ther-
apy, there is utilization of a survivorship team to assist with treatment sequelae.
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In locally advanced disease, specific attention should be paid to coordination of
care in addition to managing the physical ramifications of complex treatments
such as concurrent chemotherapy and radiation and/or complex surgery. In the
advanced stage of disease, relief of symptoms and optimization of care that is in
alignment with patient and family goals is paramount. Additionally, under-
standing when a systemic treatment is appropriate for palliation and longevity
versus when it may be contributing to hastening end of life is important. At this
stage, it is recommended to add a specialist palliative care team to assist with
ACP and transition to hospice. Palliative care is an expansive and innovative
field that has the potential to revolutionize patient care.
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Fig. 1. Summary of the palliative needs throughout the continuum of care for patients with NSCLC.
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